Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC
Status:
NOT_YET_RECRUITING
Trial end date:
2028-02-28
Target enrollment:
Participant gender:
Summary
This study is a clinical study to evaluate the safety and efficacy of Iparomlimab/Tuvonralimab Injection (QL1706, a Bifunctional Mabpair Product of Anti-PD-1 and Anti-CTLA-4 Antibodies) in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences